Live video webcast on Wednesday, July 17th at 12:00 PM ET LA JOLLA, CA, July 15, 2024 (GLOBE NEWSWIRE) -- GRI...
Marc Hertz, PhD, CEO of GRI Bio underscores importance of the interim data from their ongoing Phase 2a...
LA JOLLA, CA, July 08, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a...
Data demonstrates that NKT cells are activated in airways in IPF patients and inhibition of type 1 invariant...
LA JOLLA, CA, July 01, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a...
LA JOLLA, CA, June 28, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a...
Company is strategically building a global patent estate in key territories for a growing pipeline targeting...
LA JOLLA, CA, June 27, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a...
GRI’s common stock is expected to begin trading on a post-split adjusted basis on June 18, 2024 LA JOLLA...
Live video webcast on Tuesday, June 18th at 11:00 AM ET LA JOLLA, CA, June 11, 2024 (GLOBE NEWSWIRE) -- GRI...
Data recently presented at the 2024 American Thoracic Society International Conference and the 14th...
Data presented at the 14th International Congress on Autoimmunity Encouraging preclinical data observed to date...
Compared to controls, mice treated with GRI-0621 showed improved fibrosis and immunopathology; Inhibition of...
Live webcast fireside chat on Tuesday, May 21st at 2:40 PM ET LA JOLLA, CA, May 14, 2024 (GLOBE NEWSWIRE...
Interim data readout of Phase 2a biomarker study evaluating lead program GRI-0621 for the treatment of...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.